In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8213-8221

  Cui, Wei ^a   Yu, Chang Hong ^b   Hu, Ke Qin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2;

APOPTOSIS; ARTICLE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, NUDE; PYRAZOLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28144445331     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1044     Document Type: Article

References (40)

1. Di Bisceglie AM. Malignant neoplasms of the liver. In: Schiff ER, Sorrel MF, Maddrey WC. Schiffs disease of the liver. 8th ed. Vol. 2. Philadelphia: Lippincott-Raven Publishers; 1999. p. 1281-304.
2. Kew MC. Hepatic tumors and cysts. In: Feldman M, Sleisenger MH, Scharschmidt BF. Gastrointestinal and liver disease. 6th ed. Philadelphia: WB Saunders; 1998. p. 1364-87.
3. El-Serag HB, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
4. El-Serag HB, Mason A, Key C. Trends in survival of patients with hepatocellular carcinoma between 1997 and 1996 in the United States. Hepatology 2001; 33:62-5.
5. Willams CS, Mann M, Du Bois RN. The role of cyclooxygenase in inflammation, cancer and development. Oncology 1999;18:7908-16.
6. Hu K-Q. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. Lab Clin Med 2002;139:234-43.
7. Fosslien E. Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
8. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-96.
9. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5: 4005-12.
10. Hu K-Q, Yu C-H, Mineyama Y, McCrachen JD, Hillebrand DJ, Hasan M. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Int J Oncol 2003;22:757-63.
11. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7: 1410-8.
12. Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2000;36:885-94.
13. Cheng ASL, Chan HY, Leung W, Wong N, Johnson PJ, Sung JY. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Oncol 2003;23:113-9.
14. Wen B, Deutsch E, Eschwege P, et al. Cyclooxygenase-2 inhibitor NS-398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells. J Urol 2003;170:2036-9.
15. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-2 (COX-2) dependent and independent anticarcinogenic effect of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;69:1469-78.
16. Steinbach G, Lynch P Phillips PKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342: 1946-52.
17. Howe LR, Subbaromaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-7.
18. Zhang Z, Lai GH, Sirica A. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004; 39:1028-37.
19. Orengo IF, Gergois J, Phillpis R, Guevara A, Lewis AT, Black HS. Celecoxib, a cyclooxygenase-2 inhibitor as a potential chemopreventive to UV-induced skin cancer. Arch Dermatol 2002;138:751-5.
20. Kern MA, Schoneweiss MM, Sahi D, et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004;25:1193-9.
21. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: evidence for AKT inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-68.
22. kip1 and cell cycle arrest. Cancer Res 2004;64: 1369-76.
23. Wick M, Hurteau G, Dessev C, et al. Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002;62:1207-14.
24. Yamamoto C, Takemoto H, Kuno K, et al. Cycloprodigiosin hydrochloride, a new H(+)/Cl(-) symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 1999;30:894-902.
25. Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002;62:2343-6.
26. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. Interferon-α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001;33:346-56.
27. 1 phase-related cell cycle molecules in naturally developing hepatocellular carcinoma of Long-Evans Cinnamon rats. Int J Oncol 2004;24:1205-11.
28. Sandal T. Molecular aspects of the mammalian cell cycle and cancer. Oncologist 2002;7:73-81.
29. 1. Mol Cell Biol 1996;16: 3698-706.
30. Conner EA, Lemmer ER, Sanchez A, Factor VM, Thorgeirsson SS. E2F1 blocks and c-Myc accelerates hepatic ploidy in transgenic mouse models. Biochem Biophys Res Commun 2003;302:114-20.
31. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
32. 1-phase progression. Genes Dev 1999;13:1501-12.
33. 1 cyclin-dependent kinase. Cell 1993;75: 805-16.
34. Li MY, Deng H, Zhao JM, Dai D, Tan XY. PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 2003;9: 1220-5.
35. Toyoda M, Takagi H, Horiguchi N, et al. A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002;50:563-7.
36. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferators-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10.
37. Han SW, Inoue H, Flowers LC, Sidell N. Control of COX-2 gene expression through peroxisome proliferators-activated receptor γ in human cervical cancer cells. Clin Cancer Res 2003;9: 4627-35.
38. 2 receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 2004;314:1093-9.
39. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
40. Senior K. COX-2 inhibitors: cancer prevention or cardiovascular risk? Lancet Oncol 2005;6:68.